1. Breast Cancer Drug Avastin Faces FDA Panel
... did not make patients live longer. Furthermore, the studies found that Avastin resulted in dangerous side effects, including increased risk of internal bleeding and high blood pressure (Hellerman). Avastin's maker, Genentech, immediately filed an appeal before the FDA Commissioner Margaret Hamburg could finalize the decision. The law that created the "accelerated approval" process, which the drug was approved ... not to prescribe Avastin, according to Charlotte Arnold, a Genentech spokeswoman. Only 20-25 percent of new breast cancer patients receive the drug, down from the former 60 perc...
- Word Count: 1317
- Approx Pages: 5
- Has Bibliography
- Grade Level: Undergraduate